CA2800693A1 - Apport d'agents therapeutiques a des tissus enflammes au moyen d'agents ciblant le folate - Google Patents

Apport d'agents therapeutiques a des tissus enflammes au moyen d'agents ciblant le folate Download PDF

Info

Publication number
CA2800693A1
CA2800693A1 CA2800693A CA2800693A CA2800693A1 CA 2800693 A1 CA2800693 A1 CA 2800693A1 CA 2800693 A CA2800693 A CA 2800693A CA 2800693 A CA2800693 A CA 2800693A CA 2800693 A1 CA2800693 A1 CA 2800693A1
Authority
CA
Canada
Prior art keywords
folate
agent
targeted
liposomal composition
entrapped
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2800693A
Other languages
English (en)
Inventor
Philip Stewart Low
Scott Yew Tat Poh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CA2800693A1 publication Critical patent/CA2800693A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
CA2800693A 2010-05-28 2011-05-27 Apport d'agents therapeutiques a des tissus enflammes au moyen d'agents ciblant le folate Abandoned CA2800693A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34943410P 2010-05-28 2010-05-28
US61/349,434 2010-05-28
PCT/US2011/038437 WO2011150392A1 (fr) 2010-05-28 2011-05-27 Apport d'agents thérapeutiques à des tissus enflammés au moyen d'agents ciblant le folate

Publications (1)

Publication Number Publication Date
CA2800693A1 true CA2800693A1 (fr) 2011-12-01

Family

ID=45004436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2800693A Abandoned CA2800693A1 (fr) 2010-05-28 2011-05-27 Apport d'agents therapeutiques a des tissus enflammes au moyen d'agents ciblant le folate

Country Status (3)

Country Link
US (3) US20130071321A1 (fr)
CA (1) CA2800693A1 (fr)
WO (1) WO2011150392A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377238B (zh) 2012-07-05 2018-09-07 台湾微脂体股份有限公司 治疗关节炎的方法
BR112015022810B1 (pt) 2013-03-15 2021-11-30 Purdue Research Foundation Composto, composição e método para identificar tipo de célula alvo em amostra biológica
EP3021844B1 (fr) * 2013-07-17 2019-11-13 Council of Scientific & Industrial Research Preparation pharmaceutique pour le traitement de la diminution osseusse
WO2015077303A1 (fr) * 2013-11-19 2015-05-28 Purdue Research Foundation Méthode de sélection de patient pour le traitement de l'inflammation
EA201790378A1 (ru) * 2014-08-14 2017-07-31 Л.Е.А.Ф. ХОЛДИНГЗ ГРУП ЭлЭлСи Заключенное в липосому аффинное лекарственное средство
SG10201912650QA (en) * 2015-12-17 2020-02-27 Univ Nanyang Tech Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them
KR20230146097A (ko) 2016-08-12 2023-10-18 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
CA3090387A1 (fr) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Pralatrexate alpha-polyglutamate et utilisations associees
EP3749317A4 (fr) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC Pémétrexed alpha-polyglutamaté et utilisations associées
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
EP4087580A4 (fr) * 2020-01-07 2024-01-17 Purdue Research Foundation Conjugués stéroïdes cibles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
JPS6252188A (ja) 1985-08-27 1987-03-06 エスケ−化研株式会社 耐火性能の優れた組成物
GB2304438A (en) 1995-08-17 1997-03-19 Kenneth Austin Re-configurable application specific device
WO1997031624A1 (fr) 1996-02-27 1997-09-04 Purdue Research Foundation Systeme d'apport de liposome
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US20030026831A1 (en) * 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
WO2002087424A2 (fr) 2001-05-02 2002-11-07 Purdue Research Foundation Traitement et diagnostic de maladies associees aux macrophages
EP1371362A1 (fr) 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition pour le traitement de troubles inflammatoires
US20050152962A1 (en) 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
JP2007526238A (ja) 2003-05-06 2007-09-13 パーデュー・リサーチ・ファウンデーション マクロファージまたは葉酸受容体を標的とする狼瘡治療法
WO2007006041A2 (fr) * 2005-07-05 2007-01-11 Purdue Research Foundation Procede d'imagerie et therapeutique utilisant des monocytes
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
EP2231195B1 (fr) * 2007-12-04 2017-03-29 Arbutus Biopharma Corporation Lipides de ciblage
AU2009257279A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2011119995A2 (fr) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations et procédés d'utilisation

Also Published As

Publication number Publication date
US20200297632A1 (en) 2020-09-24
WO2011150392A1 (fr) 2011-12-01
US20130071321A1 (en) 2013-03-21
US20220054417A1 (en) 2022-02-24
US11185505B2 (en) 2021-11-30

Similar Documents

Publication Publication Date Title
US11185505B2 (en) Delivery of agents to inflamed tissues using folate-targeted liposomes
JP6612905B2 (ja) 薬剤のミトコンドリア輸送のためのナノ粒子
Lee et al. Nano-sized metabolic precursors for heterogeneous tumor-targeting strategy using bioorthogonal click chemistry in vivo
ES2301871T3 (es) Corticosteroides encapsulados en vesiculas para el tratamiento del cancer.
Yang et al. A positron emission tomography image-guidable unimolecular micelle nanoplatform for cancer theranostic applications
Sou et al. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo
JP2014527071A (ja) Ｈ−ホスホネートによるナノ粒子ｐｅｇの改変
BR112013005202B1 (pt) Lipídeo legumaína-alvo, composição de nanopartículas de legumaína-alvo e usos dos mesmos
US20240066144A1 (en) Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
Aranda-Lara et al. Radiolabeled liposomes and lipoproteins as lipidic nanoparticles for imaging and therapy
Gouveia et al. Non-biologic nanodelivery therapies for rheumatoid arthritis
US9457082B2 (en) Liposome including complex of hydrophobic active ingredient and polypeptide and use of the liposome
ES2314210T3 (es) Composicion para tratamiento de trastornos inflamatorios.
US20030170299A1 (en) Therapeutic methods for acute myeloid leukemia
KR20130117361A (ko) 양친성 저분자량 히알루론산 복합체를 포함하는 나노 입자 및 그의 제조 방법
Zhao et al. Self-assembled amphiphile-based nanoparticles for the inhibition of hepatocellular carcinoma metastasis via ICAM-1 mediated cell adhesion
Medina et al. Using Alendronic Acid Coupled Fluorescently Labelled SM Liposomes as a Vehicle for Bone Targeting
Ahmed et al. Synthesis, Characterization, and In Vivo Distribution of 99mTc Radiolabelled Docetaxel Loaded Folic Acid-Thiolated Chitosan Enveloped Liposomes
Cvjetinović et al. 177Lu–labeled micro liposomes as a potential radiosynoviorthesis therapeutic agent
CN117624582A (zh) 含氟dspe-peg2000、其应用、包含其的纳米颗粒和应用
Lecommandoux et al. Polymeric micelles and vesicles: Biological behavior evaluation using radiolabeling techniques

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160527